Rinamet Tablet 2.5/500 mg
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
MFDS item code 201905401 · Approved 2019.07.30
This product's status changed to Expired on 2024.07.30. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used to assist in blood sugar control for patients with type 2 diabetes who are taking linagliptin and metformin together. It is administered in conjunction with dietary and exercise therapies to effectively manage blood sugar levels. This helps stabilize blood sugar fluctuations and contribute to reducing the risk of complications. Better results can be expected when used alongside improvements in the patient's lifestyle.
The dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment experience who cannot achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily; the dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching to this medicine from combination therapy with linagliptin and metformin should take the same doses of linagliptin and metformin they were previously taking as the initial dose. 3. Inadequate glycemic control with concomitant insulin and metformin therapy: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient’s current metformin dose. When this medicine is administered with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Careful Administration). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with another oral antihyperglycemic agent to this medicine. Any change in a treatment regimen for type 2 diabetes may alter glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used, with the following dosage adjustments, in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis. Treatment should not be initiated with this medicine because the starting dose of metformin is 500mg or 850mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with impaired liver function because it contains metformin (see Precautions for Use, 1. Contraindications).
This medication can cause serious health risks due to a rare side effect known as lactic acidosis, so it should not be used, particularly in patients with impaired kidney function or acute illnesses. Patients with allergies to the active ingredients or components of this medication, or with certain diabetic conditions such as type 1 diabetes or diabetic ketoacidosis, should also refrain from taking it. It should be avoided in patients with severely impaired kidney function, dehydration, severe infections, heart failure, liver dysfunction, acute alcohol intoxication or chronic alcoholism. Women who are pregnant or breastfeeding are also advised not to use this medication, and women planning to become pregnant should be especially cautious. When used with other blood glucose-lowering agents, there is a risk of hypoglycemia, so patients should be well informed of hypoglycemic symptoms and dosage adjustments may be necessary if needed. This medication is affected by kidney function, thus regular kidney function tests should be performed, and if kidney function declines, dosage adjustments or discontinuation may be required. Acute pancreatitis, severe arthralgia, or bullous skin diseases may occur, so if such symptoms arise, immediate consultation with medical personnel is necessary. Vitamin B12 levels may decrease, so monitoring through blood tests is essential during prolonged use. This medication can interact with several other drugs, therefore, it is crucial to inform medical staff if taking other medications, especially those that may affect kidney function. It should not be used during pregnancy or breastfeeding, and safety in children has not been established. Elderly persons should be administered carefully due to common declines in kidney function and routine monitoring of kidney function is necessary. In cases of overdose, serious side effects such as lactic acidosis may occur, so dosage should be adhered to, and if unusual symptoms arise, immediate medical attention should be sought. Store in a place out of reach of children, avoid moisture, and do not transfer to another container.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture and should be stored in a tightly closed container. The best storage temperature is between 1 to 30 degrees Celsius. This helps maintain the efficacy of the medication for a longer time.
Bright yellow, oval film-coated tablet with a convex surface on both sides.
60 tablets (10 tablets/PTP x 6)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Linagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Anguk Pharm Co., Ltd.
Linagliptin 2.5mg · Metformin Hydrochloride 1000mg
Prescription medication · Combination
Hanmi Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Kukje Pharmaceutical Co., Ltd.
CombinationLinagliptin 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
International Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.